Naked monoclonal antibodies or mAbs bind to specific epitopes or target molecules on cells. Therapeutic uses of mAbs have been limited by several factors, including cancer cell specificity, tumor penetration, as well as manufacturing issues. BioAtla's human CAB mAbs are optimized and expressed in our proprietary CIAO! system. CAB mAbs have a high Therapeutic Index because they are only active under the physiological conditions associated with disease. This unique capability enables development of therapeutics for targets that are also expressed on healthy tissues, while minimizing undesirable side effects.
CAB Portfolio
Pipeline
- STS & Bone Sarcoma
- NSCLC
- Ovarian Cancer*
- Interim sarcoma update Q1 earnings
- Phase 2 interim NSCLC clinical data Q2 earnings
- Ovarian IIT dosing 1H2022
- NSCLC
- Melanoma
- SCCHN
- Ovarian Cancer*
- Phase 2 interim melanoma and NSCLC data mid-year / 2H2022
- SCCHN trial dosing 3Q 2022
- Ovarian IIT dosing 1H2022
- Multiple tumor types**
- IND submission 2023
- Multiple tumor types**
- IND submission 2024
- Multiple tumor types**
- Trial dosing 1H2022
- Adenocarcinoma**
- Multiple tumor types**
- IND submission and Phase 1 initiation 2022
- Multiple tumor types
- IND submission 2023
- Multiple tumor types**
- IND submission 2023
& ADCS
Programs
oncology
BioAtla's CAB anti-ROR2 ADC is engineered to selectively bind tumor cells expressing the ROR2 protein and avoid binding to normal tissue expressing this protein. BA3021 is being evaluated both as monotherapy and in combination with a PD-1 inhibitor (nivolumab) in patients with ROR2-expressing melanoma, non-small cell lung cancer (NSCLC) and ovarian cancer.
HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family. Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. In recent years the protein has become an important biomarker and target of therapy for approximately 30% of breast cancer patients. Amplification, also known as the over-expression of the ERBB2 gene, occurs in approximately 15-30% of breast cancer. It is strongly associated with increased disease recurrence and a poor prognosis; however, drug agents targeting HER2 in breast cancer have significantly positively altered the otherwise poor-prognosis natural history of HER2-positive breast cancer. Over-expression is also known to occur in ovarian, stomach, adenocarcinoma of the lung and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma, e.g. HER2 is over-expressed in approximately 7-34% of patients with gastric cancer and in 30% of salivary duct carcinomas.
With its elevated receptor copy number and relatively homogeneous expression following gene amplification, HER2 represents an attractive antigen to target via CAR-T; unfortunately, severe toxicity related to off-tumor binding of traditional CAR-T's to HER2 present in normal tissue may limit the use of traditional HER2 CAR-T therapy, To circumvent this issue Exuma developed a "logic-gated" HER2-targeted CAR-T based upon a HER2 CAB that preferentially recognizes HER2 in the tumor microenvironment, thereby limiting on-target toxicity of low HER2 levels expressed in normal tissue.- Non Small Cell Lung Cancer (NSCLC)
- Melanoma
- STS & Bone Sarcoma
- NSCLC
- Ovarian Cancer*
- NSCLC
- Melanoma
- HNC
- Ovarian Cancer*
- RCC
- NSCLC / SCLC
- HCC
- Melanoma
- Bladder
- Gastric
- Cervical Cancer
- Colorectal
- NSCLC / SCLC
- Ovarian
- Prostate Cancer**
- TNBC
- HNC
- Melanoma
- NSCLC / SCLC
- Pancreatic
- Prostate Cancer**
- Sarcoma
- Coloractal Cancer**
- HNC
- NSCLC
- Pancreatic
- TNBC
- Breast
- Colon
- Kidney
- Ovary
- Prostate
- Bladder
- Pancreatic Cancer**
- TNBC